Immunocore reaches target enrollment in registrational trial
Immunocore announced it achieved the enrollment goal for the TEBE-AM Phase 3 trial of KIMMTRAK in advanced melanoma. Topline data is expected as early as the end of 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day